The Intercept IQ™ Pipeline
The Intercept IQ™ platform is designed to support the discovery, development, and commercialization of molecular diagnostics across metabolic disease, oncology, neurology, and future disease applications. Each program leverages a shared foundation of liquid biopsy, multi-omic biomarker analysis, artificial intelligence, and precision molecular diagnostics.
Four active programs across three therapeutic areas — each built on the shared Intercept IQ™ molecular intelligence platform, leveraging liquid biopsy, multi-omic biomarker analysis, and AI-driven analytics.
Focus. Early detection and longitudinal monitoring of autoimmune beta-cell injury associated with Type 1 Diabetes.
Applications
Primary Technologies
Focus. Detection of beta-cell dysfunction and progressive metabolic disease.
Applications
Primary Technologies
In partnership with Kiluma Biosciences
Focus. Blood-based molecular diagnostics for pancreatic cancer.
Applications
Primary Technologies
In partnership with Kivara Neurosciences
Focus. Blood-based molecular diagnostics for neurodegenerative disease.
Current Programs
Applications
Primary Technologies
Blood-based molecular diagnostics.
Integrated biological data from multiple molecular layers.
Machine learning for multidimensional biomarker interpretation.
Monitoring biological change over time rather than relying on single-point measurements.
One specimen. Ten disciplined stages. A clinically actionable report.
A single end-to-end workflow — from patient blood draw to clinical report — that every disease program runs through.
Blood Collection
Sample Stabilization
Plasma Isolation
Cell-Free DNA Extraction
Molecular Analysis
Quality Control
Multi-Omic Integration
AI Analysis
Disease-Specific Algorithms
Clinical Report
ReportEvery disease program — metabolic, oncology, and neurology — runs through the same validated workflow, so new indications launch on proven infrastructure rather than rebuilt pipelines.
Four active programs across three therapeutic areas — each built on the shared Intercept IQ™ molecular intelligence platform, with a clear path to additional disease areas.
Molecular diagnostics for diabetes and metabolic dysfunction.
Beta Intercept™ T1D
Beta Intercept™ T2D
Liquid-biopsy interception of early-stage solid tumors.
Onco Intercept™
Initial focus: Pancreatic Cancer
Molecular signals for neurodegeneration and autoimmune neurology.
Neuro Intercept AD
Neuro Intercept MS
The platform's architecture enables expansion into additional disease areas.
Potential future applications
Kihealth is building a scalable molecular diagnostics platform designed to transform how diseases are detected, monitored, and managed. By combining liquid biopsy technologies, multi-omic biomarker discovery, artificial intelligence, and clinical research, the Intercept IQ™ platform establishes a common scientific foundation that supports multiple disease-specific diagnostic programs. As new biomarkers are discovered and validated, the platform is designed to expand into additional therapeutic areas, creating a continuously evolving ecosystem for precision diagnostics.
